



an Open Access Journal by MDPI

## Novel Progress in Non-alcoholic Fatty Liver Diseases

Guest Editor:

### Dr. Kristine Griffett

Department of Anatomy,  
Physiology and Pharmacology,  
College of Veterinary Medicine,  
Auburn University, Auburn, AL  
36849, USA

Deadline for manuscript  
submissions:

**closed (30 April 2023)**

### Message from the Guest Editor

Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of complications from simple steatosis, steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). NAFLD is the most prevalent liver disease worldwide. Recently, an increasing number of NAFLD patients have had accompanying co-morbidities, including type 2 diabetes (T2D), obesity, and cardiovascular disease, leading to the designation of a new subtype of liver disease: metabolic-associated fatty liver disease (MAFLD). There is still some ongoing etymological debate regarding the etiology and diagnosis of MAFLD vs. NAFLD. This Special Issue will allow researchers and clinicians to clarify the commonalities and differences among these liver diseases so that we can better understand pathogenesis and therapeutic targets to design new and effective treatment options. Here, we will highlight articles in epidemiology, cellular and molecular mechanisms of liver disease, animal models to study NAFLD and MAFLD, as well as novel therapies, and clinical aspects of liver diseases as we currently understand them.



[mdpi.com/si/149917](https://mdpi.com/si/149917)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI